SCHEMBL3872897

SCHEMBL3872897

CN1CCCC(CNc2ccccc2N)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.43
ADRA2A P08913 2/20 0.43
CHRM1 P11229 2/20 0.43
DRD1 P21728 2/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
ADRA1A P35348 2/20 0.43
OPRM1 P35372 2/20 0.43
DRD3 P35462 2/20 0.43
KCNH2 Q12809 2/20 0.43
HRH3 Q9Y5N1 2/20 0.43
HTR2B P41595 2/20 0.43
ABCB11 O95342 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2B P18089 1/20 0.43
CHRM3 P20309 1/20 0.43
PTGS1 P23219 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3882481 0.99 CHRM2 (0.42) CHRM2ADRA2ACHRM1DRD1SLC6A2
SCHEMBL3876083 0.84 NSD2 (0.48) HDAC1HDAC2MAPTHDAC3HDAC4
SCHEMBL20837293 0.81 MAPT (0.53) LMNATP53CYP2D6HDAC1HDAC2
SCHEMBL3993803 0.80 ALDH1A1 (0.43) LMNAHDAC1HDAC2KDM4EGAA
SCHEMBL4938177 0.80 ALDH1A1 (0.43) LMNAHDAC1HDAC2KDM4EGAA
SCHEMBL8564453 0.80 KDM4E (0.56) LMNATP53CYP2D6HDAC1HDAC2
SCHEMBL29922576 0.80 KDM4E (0.56) LMNATP53CYP2D6HDAC1HDAC2
SCHEMBL30693377 0.78 PTGER4 (0.47) LMNATP53CYP2D6HDAC1HDAC2
SCHEMBL977627 0.78 PTGER4 (0.47) LMNATP53CYP2D6HDAC1HDAC2
SCHEMBL13875252 0.76 ACKR3 (0.58) HTR6KDM4EBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538115-B2 Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-05-26 US disclosed
EP-1487821-B1 BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES BOEHRINGER INGELHEIM PHARMA (DE) 2007-03-21 EP disclosed
US-7026312-B2 Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-04-11 US disclosed
US-20050215546-A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-09-29 US disclosed
US-20030236282-A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236282-A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof P2RX5, CALCRL, ADRA1D CHRM2 148/4885ADRA2A 33/4885CHRM1 56/4885
US-20050215546-A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof P2RX3, P2RX5, P2RX2 CHRM2 48/4885ADRA2A 29/4885CHRM1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.